Discover
BCRX
BioCryst Pharmaceuticals, Inc.
10.34
1 x 10.21
1 x 10.36
bid
ask
+
0.50
5.08%
96 @ 04:00 PM
10.21 -0.13 (1.23%)
| Ytd | 32.56% | |
| 1y | 26.10% |
9.78
day range
10.59
6.00
52 week range
11.22
| Open | 10.34 | Prev Close | 9.84 | Low | 9.78 | High | 10.59 | Mkt Cap | 2.63B |
| Vol | 0.00 | Avg Vol | 4.83M | EPS | -1.50 | P/E | -6.89 | Forward P/E | 10.47 |
| Beta | 0.55 | Short Ratio | 4.70 | Inst. Own | 102.68% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-03 | 50-d Avg | 9.33 | 200-d Avg | 8.31 | 1yr Est | 20.82 |
| Income Statement | |||
| Total Revenue | 218.25M | ||
| Revenues (USD) | 218.25M | ||
| Cost of Revenue | 3.84M | ||
| Gross Profit | 214.41M | ||
| Operating Expenses | 115.95M | ||
| Research and Development Expense | 51.97M | ||
| Selling, General and Administrative Expense | 63.98M | ||
| Operating Income | 98.47M | ||
| Interest Expense | 21.71M | ||
| Income Tax Expense | 1.08M | ||
| Net Income | 78.40M | ||
| Net Income Common Stock | 78.40M | ||
| Net Income Common Stock (USD) | 78.40M | ||
| Consolidated Income | 78.40M | ||
| Earnings per Basic Share | 0.31 | ||
| Earnings per Basic Share (USD) | 0.31 | ||
| Earnings per Diluted Share | 0.30 | ||
| Earning Before Interest & Taxes (EBIT) | 101.19M | ||
| Earning Before Interest & Taxes (USD) | 101.19M | ||
| Weighted Average Shares | 254.48M | ||
| Weighted Average Shares Diluted | 265.17M | ||
| Balance Sheet | |||
| Cash and Equivalents | 155.45M | ||
| Cash and Equivalents (USD) | 155.45M | ||
| Investments | 197.60M | ||
| Investments Current | 197.60M | ||
| Trade and Non-Trade Receivables | 110.76M | ||
| Current Assets | 484.68M | ||
| Property, Plant & Equipment Net | 21.67M | ||
| Total Assets | 557.85M | ||
| Debt Current | 46.81M | ||
| Total Debt | 836.65M | ||
| Current Liabilities | 208.85M | ||
| Debt Non-Current | 789.83M | ||
| Total Liabilities | 1.01B | ||
| Accumulated Retained Earnings (Deficit) | -2.15B | ||
| Accumulated Other Comprehensive Income | -528.00K | ||
| Shareholders Equity | -454.29M | ||
| Shareholders Equity (USD) | -454.29M | ||
| Assets Non-Current | 73.17M | ||
| Total Debt (USD) | 836.65M | ||
| Deferred Revenue | 25.78M | ||
| Inventory | 38.00M | ||
| Liabilities Non-Current | 803.29M | ||
| Trade and Non-Trade Payables | 11.46M | ||
| Cash Flow | |||
| Depreciation, Amortization & Accretion | 513.00K | ||
| Net Cash Flow from Financing | -11.15M | ||
| Net Cash Flow / Change in Cash & Cash Equivalents | -16.99M | ||
| Capital Expenditure | -209.00K | ||
| Issuance (Purchase) of Equity Shares | 6.20M | ||
| Issuance (Repayment) of Debt Securities | -13.71M | ||
| Net Cash Flow from Investing | -110.15M | ||
| Net Cash Flow - Investment Acquisitions and Disposals | -109.94M | ||
| Net Cash Flow from Operations | 104.34M | ||
| Effect of Exchange Rate Changes on Cash | -35.00K | ||
| Share Based Compensation | 14.69M | ||